Ingevity (NYSE:NGVT) Announces Quarterly Earnings Results, Beats Estimates By $0.41 EPS

Ingevity (NYSE:NGVT) posted its earnings results on Wednesday. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.33 by $0.41, FiscalAI reports. Ingevity had a return on equity of 261.97% and a net margin of 4.65%.The firm had revenue of $314.10 million for the quarter, compared to analyst estimates of $312.20 million. Ingevity updated its FY 2026 guidance to 5.000-5.450 EPS.

Ingevity Stock Performance

NYSE:NGVT traded up $3.75 during mid-day trading on Friday, reaching $73.94. 146,858 shares of the stock were exchanged, compared to its average volume of 294,670. The stock has a market capitalization of $2.57 billion, a P/E ratio of 50.31 and a beta of 1.16. Ingevity has a 1 year low of $39.74 and a 1 year high of $79.29. The company has a 50 day simple moving average of $71.63 and a 200-day simple moving average of $70.95. The company has a quick ratio of 0.92, a current ratio of 1.42 and a debt-to-equity ratio of 27.83.

Insiders Place Their Bets

In other news, SVP Terrance M. Dyer sold 496 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $68.49, for a total value of $33,971.04. Following the completion of the sale, the senior vice president directly owned 7,202 shares of the company’s stock, valued at approximately $493,264.98. This represents a 6.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.88% of the company’s stock.

Institutional Trading of Ingevity

Institutional investors and hedge funds have recently bought and sold shares of the business. Global Retirement Partners LLC purchased a new position in Ingevity during the 4th quarter worth $27,000. Meeder Asset Management Inc. purchased a new stake in shares of Ingevity in the fourth quarter valued at about $33,000. Geneos Wealth Management Inc. raised its holdings in shares of Ingevity by 85.8% in the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after buying an additional 387 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Ingevity during the second quarter worth about $46,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Ingevity during the fourth quarter worth about $47,000. Hedge funds and other institutional investors own 91.59% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on NGVT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ingevity in a research report on Friday, July 17th. Wall Street Zen raised Ingevity from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $80.00.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.